![]()
|
|
||||||||
J Biol Chem, Vol. 273, Issue 33, 21423-21429, August 14, 1998
From the Angiogenesis Research Center, Cardiovascular Division,
Department of Medicine Beth Israel Deaconess Medical Center and Harvard
Medical School, Boston, Massachusetts 02215
The nuclear transcription factor c-Myb, which is
highly expressed in hematopoietic cells, has been shown to be
functional in NIH 3T3 cells: cells that do not possess detectable
levels of c-Myb. To identify endogenous target genes of c-Myb in
fibroblasts, RNA isolated from NIH 3T3 cells stably transfected with a
full-length or a dominant negative c-myb construct (GREMyb
and GREMEn, respectively) was subjected to differential display
analysis. 5'-Rapid amplification of cDNA ends of a selected band,
sequencing, and a nucleotide homology search led to the identification
of thrombospondin 2 (TSP 2) as the gene product repressed in GREMyb and
induced in GREMEn cells. The pattern of TSP 2 expression during the
cell cycle was consistent with c-myb-dependent
regulation. The possibility that the identified transcript was TSP 1, a
homologous product known to be repressed by v-Src, c-Jun, and v-Myc,
was ruled out by using a TSP 2-specific DNA probe and by showing a
distinct pattern of regulation of TSP 1 and TSP 2 expression. Nuclear
run-on and TSP 2 promoter-reporter (chloramphenicol acetyltransferase) assays showed similar transcriptional levels in GREMyb and NIH 3T3
cells. However, mRNA stability studies showed a much shorter TSP 2 mRNA half-life in GREMyb compared with wild type NIH 3T3 cells,
suggesting that c-myb affects TSP 2 expression via a
post-transcriptional mechanism. The implications of a
protooncogene-mediated suppression of TSP expression are discussed.
This article has been cited by other articles:
![]() |
G. Potikyan, R. O.V. Savene, J. M. Gaulden, K. A. France, Z. Zhou, E. S. Kleinerman, S. L. Lessnick, and C. T. Denny EWS/FLI1 Regulates Tumor Angiogenesis in Ewing's Sarcoma via Suppression of Thrombospondins Cancer Res., July 15, 2007; 67(14): 6675 - 6684. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-M. You, I. N. Mungrue, W. Kalair, T. Afroze, B. Ravi, A. M. Sadi, R. Gros, and M. Husain Conditional Expression of a Dominant-Negative c-Myb in Vascular Smooth Muscle Cells Inhibits Arterial Remodeling After Injury Circ. Res., February 21, 2003; 92(3): 314 - 321. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Janz, C. Sevignani, K. Kenyon, C. V. Ngo, and A. Thomas-Tikhonenko Activation of the Myc oncoprotein leads to increased turnover of thrombospondin-1 mRNA Nucleic Acids Res., June 1, 2000; 28(11): 2268 - 2275. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. V. Ngo, M. Gee, N. Akhtar, D. Yu, O. Volpert, R. Auerbach, and A. Thomas-Tikhonenko An in Vivo Function for the Transforming Myc Protein: Elicitation of the Angiogenic Phenotype Cell Growth Differ., April 1, 2000; 11(4): 201 - 210. [Abstract] [Full Text] |
||||
![]() |
T. Afroze and M. Husain c-Myb-binding Sites Mediate G1/S-associated Repression of the Plasma Membrane Ca2+-ATPase-1 Promoter J. Biol. Chem., March 17, 2000; 275(12): 9062 - 9069. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |